[Antiarrhythmic therapy in patients with heart failure]

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Context:

• Severe chronic heart failure patients face high mortality from ventricular arrhythmias.
• Current therapeutic strategies include antiarrhythmic drugs and implantable cardioverter-defibrillators (ICDs).
• Selecting the optimal strategy for individual patients remains a significant clinical challenge.

Purpose:

• To evaluate the efficacy of antiarrhythmic drug therapy versus ICDs in reducing sudden cardiac death.
• To assess the role of different antiarrhythmic drug classes in managing arrhythmias in heart failure.
• To determine the most beneficial therapeutic approach for primary and secondary prevention of sudden arrhythmic death.

Summary:

• ICDs are superior to antiarrhythmic drugs for secondary prevention of sudden death in heart failure.
• ICDs show favorable results for primary prevention in selected high-risk populations.
• Beta-blockers offer antiarrhythmic benefits without increasing proarrhythmia; other antiarrhythmics are generally not recommended due to increased mortality risks.
• Amiodarone and dofetilide can be used for atrial fibrillation management, but dofetilide requires close monitoring.
• For chronic atrial fibrillation, rate control and anticoagulation are primary goals.

Impact:

• ICD therapy significantly reduces cardiac mortality in severe heart failure patients.
• Antiarrhythmic drug therapy is not routinely justified for high-risk patients.
• Concomitant antiarrhythmic drug therapy, like sotalol, may reduce ICD shock delivery.
• Findings guide clinical decision-making in managing arrhythmias and preventing sudden death in heart failure.